Longeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
September 26, 2024 09:05 ET
|
Longeveron
Longeveron to attend Cell & Gene Meeting on the Mesa to highlight its cellular therapy program in Alzheimer's disease and CDMO facilities and services.
Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)
September 03, 2024 09:00 ET
|
Longeveron
Longeveron announces positive Type C meeting with FDA, clarifying regulatory pathway to BLA submission for Lomecel-B for hypoplastic left heart syndrome.
Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024 16:05 ET
|
Longeveron
Longeveron reports Q2 2024 financial results and provides business update. Phase 2b clinical trial in HLHS achieves 70% enrollment.
Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)
July 28, 2024 16:51 ET
|
Longeveron
Longeveron Phase 2a clinical results in Alzheimer's Disease selected for Featured Research oral presentation at Alzheimer’s Association International Conf
Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease
July 17, 2024 08:00 ET
|
Longeveron
Longeveron announces FDA has granted Fast Track designation to cellular therapy Lomecel-B(TM) for the treatment of mild Alzheimer’s Disease.
Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors
July 08, 2024 09:00 ET
|
Longeveron
Gene therapy pioneer Dr. Roger Hajjar elected to Longeveron Board of Directors as company advances it novel cellular therapy across multiple indications.
Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
June 17, 2024 09:00 ET
|
Longeveron
Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th.
Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease
June 11, 2024 09:00 ET
|
Longeveron
Investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B as a potential adjunct treatment for HLHS.
Longeveron® to Attend BIO International Convention 2024
May 28, 2024 08:05 ET
|
Longeveron
Longeveron to attend BIO 2024, exploring potential partnership and strategic opportunities for its Alzheimer’s disease program.
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 16:05 ET
|
Longeveron
Longeveron announces 2024 Q1 financial results and business update. Phase 2b study in rare pediatric disease HLHS on track to complete enrollment in 2024.